ABIO ARCA biopharma, Inc. gains 112% Jun 4, 2020

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.http://www.priceseries.com/trade/ABIO-ARCA-biopharma-Inc-stock-gains-112-percent-a-Trade-Record-by-priceSeries-2020052720200604.html